Takeda

Takeda, headquartered in Japan and operating in Pharmaceutical Preparation Manufacturing, has set ambitious climate commitments.

In 2025, Takeda reported approximately 246,000,000 kg CO2e in Scope 1 emissions, 28,000,000 kg CO2e in market-based Scope 2 emissions, and 2,536,000,000 kg CO2e in Scope 3 emissions.

Takeda is committed to several significant emissions reduction targets:

• Near-term Scope 1 & 2 Reduction (SBTi): Takeda Pharmaceutical Company commits to reduce absolute Scope 1 and 2 GHG emissions by 65% by FY2030 from a FY2016 base year.
• Near-term Scope 3 Reduction (SBTi): Takeda Pharmaceutical Company commits to reduce absolute Scope 3 GHG emissions by 25% by FY2030 from a FY2022 base year.
• Long-term Scope 1 & 2 Reduction (SBTi): Takeda Pharmaceutical Company commits to reduce absolute Scope 1 and 2 GHG emissions by 90% by FY2035 from a FY2016 base year.
• Long-term Scope 3 Reduction (SBTi): Takeda Pharmaceutical Company commits to reduce absolute Scope 3 GHG emissions by 90% by FY2040 from a FY2022 base year.
• Net-Zero Target (SBTi): Takeda Pharmaceutical Company Limited commits to reach net-zero greenhouse gas emissions across the value chain by FY2040. This includes net-zero for Scope 1 and 2 emissions before 2035 and for Scope 3 emissions before 2040.

Earlier commitments included a 30% reduction in CO2 emissions from energy sources (Scope 1 and Scope 2) by fiscal 2030 from fiscal 2015 levels. Takeda Pharmaceutical Company also previously committed to reducing absolute Scope 1 and 2 GHG emissions by 40% by FY2025 from a FY2016 base year, and that 67% of its suppliers by emissions covering purchased goods and services, capital goods and upstream transportation and distribution, will have science-based targets by 2024.